At Diversified Insurance Brokers, we help clients with a history of skin cancer—basal cell, squamous cell, or melanoma—secure affordable life insurance from our network of 100+ A-rated carriers. Skin cancer is one of those categories where the diagnosis label alone doesn’t tell the underwriting story. A fully excised basal cell carcinoma with clear margins and routine dermatology follow-ups is very different from an invasive melanoma with higher Breslow thickness, ulceration, or lymph node involvement. Insurers know this. The problem is that many applications don’t explain it clearly, so the underwriter defaults to conservative assumptions that can lead to higher pricing, a postponement, or an avoidable decline.

Because we place these cases every week, we know what details carriers actually weigh, which companies tend to be more favorable for each profile, and how to position your file so underwriting focuses on stability, clean margins, and long-term follow-up compliance. Our process is simple: we help you present the right medical facts in the right way, then we place your case with carriers whose underwriting rules align with your specific history. That strategy matters whether you’re shopping term coverage for income protection, permanent coverage for longer-term goals, or a blend that keeps costs efficient while still providing meaningful protection.

It’s also important to understand that “skin cancer” covers a wide spectrum of risk. Non-melanoma skin cancers—like basal cell and squamous cell—are often underwritten more favorably once treated, especially when there’s no recurrence and follow-up care is documented. Melanoma is evaluated more conservatively because the potential for recurrence and metastasis is more variable, but favorable melanoma histories can still qualify for strong traditional coverage when the pathology and follow-up timeline support stability. The key is getting the details right and avoiding one-size-fits-all underwriting channels that do not shop carriers intelligently.

Can You Get Life Insurance After Skin Cancer?

In many cases, yes. A skin cancer history does not automatically disqualify you from life insurance. What determines approval and pricing is the specific diagnosis type, the pathology details (especially for melanoma), the success of treatment, the time since treatment, and your follow-up history. Underwriters want to see that the cancer was treated properly, that margins were clear, that there is no evidence of ongoing disease, and that you have a documented surveillance plan with dermatology or oncology if needed.

Where people run into problems is assuming all carriers treat skin cancer the same. They don’t. Some carriers are quite favorable for non-melanoma histories and can be very reasonable once treatment is complete. Others are more conservative, particularly if the application is submitted without complete pathology or if follow-up is unclear. That’s why strategy matters. You don’t want a decline on your record simply because your case was sent to a carrier that wasn’t a fit, or because the file lacked the details the underwriter needed to evaluate the real risk.

If you have other medical conditions alongside your skin cancer history—blood pressure, cholesterol, sleep apnea, diabetes, or anything else—carriers may combine risks. In those situations, it helps to understand how multi-condition underwriting works and why carrier selection becomes even more important. This guide is a useful starting point: life insurance with pre-existing conditions.

How Skin Cancer Affects Life Insurance Underwriting

Skin cancer underwriting is documentation-driven. Underwriters are not only asking, “Did you have cancer?” They are asking, “What does that diagnosis mean in terms of recurrence risk, metastasis risk, and long-term stability?” For basal cell and squamous cell carcinomas, many underwriters view these as localized skin events once treated, especially when excision is complete and follow-ups are routine. For melanoma, the analysis becomes more detailed because pathology features can meaningfully change risk.

Underwriters typically focus on the following core themes. First is diagnosis type. Basal cell carcinoma is generally the most favorable, squamous cell carcinoma is often still very insurable when localized and treated, and melanoma tends to trigger more conservative review. Second is pathology and staging. For melanoma, details like Breslow thickness, ulceration, mitotic activity, Clark level (sometimes referenced), and sentinel lymph node biopsy results can be pivotal. Third is treatment and margins. A clean excision with clear margins and no additional therapy often supports more favorable outcomes compared to cases requiring extensive treatment.

Fourth is time since treatment. Skin cancer is underwritten heavily on timeline. The longer you are disease-free, the more carrier options typically open up, and the more competitive outcomes can become. Fifth is recurrence and surveillance. Regular dermatology visits, documented skin exams, and clean follow-up notes demonstrate stability and compliance, which underwriters like. Finally, overall health still matters. Even with a favorable skin cancer history, tobacco use, significant build concerns, uncontrolled blood pressure, or other medical issues can influence the final class.

Basal Cell and Squamous Cell: What Underwriters Typically Look For

Basal cell carcinoma (BCC) is often viewed as one of the most favorable cancer histories in life insurance underwriting—particularly when it was treated promptly, fully excised, and followed by routine dermatology checks. Underwriters usually want to confirm the lesion type, treatment method, and that margins were clear. If a case involves multiple lesions over time, carriers may still be reasonable, but they often want to see a pattern of consistent surveillance and no aggressive features.

Squamous cell carcinoma (SCC) can be similarly insurable when it is localized and fully treated, but underwriting may become more cautious if pathology suggests deeper invasion, high-risk locations, or more aggressive behavior. Underwriters generally look for complete treatment documentation, no evidence of spread, and a stable follow-up plan. When squamous cell has been recurring frequently, it may signal higher risk behavior or sun exposure patterns, which can lead to more conservative pricing. Even then, carrier selection can make a significant difference because not all companies interpret recurrence patterns the same way.

For many non-melanoma histories, the underwriting path can be fairly straightforward when documentation is clean. The biggest avoidable mistake is submitting an application with incomplete details, forcing the underwriter to request extra records and creating delays. Our goal is to help your file arrive “underwriter-ready,” so the decision is based on complete information from the start.

Melanoma Underwriting: Why Details Matter So Much

Melanoma underwriting is where precision matters. Underwriters are not looking for generic statements like “melanoma removed.” They want specifics—because the difference between an in situ melanoma and an invasive melanoma with higher Breslow thickness can change underwriting dramatically. The pathology report is often the single most important piece of evidence in a melanoma file. Breslow thickness (often measured in millimeters) is commonly referenced because it correlates with risk. Ulceration and sentinel lymph node status are also key because they influence staging and the insurer’s view of recurrence potential.

Time since treatment is equally important. Many carriers evaluate melanoma through a combination of stage and disease-free interval. Favorable pathology with a strong disease-free timeline can open up traditional term and permanent options with reasonable ratings. More advanced pathology often results in postponement until the carrier’s waiting period is satisfied, followed by a re-evaluation. The biggest advantage of working with an independent brokerage is that we can help you avoid wasting time on carriers whose waiting period or appetite does not fit your profile.

Follow-up care matters too. Underwriters want evidence that you are being monitored appropriately. Regular dermatology notes, oncology follow-ups when relevant, and statements that there is no evidence of disease can support better outcomes. Underwriters also want to see that there are no related complications, no suspicious lesions being investigated, and no signs of systemic involvement. When these elements are well-documented, the file reads as stable—and stable is what carriers price best.

What Medical Details Carriers Commonly Request

Life insurance carriers typically request a combination of diagnosis confirmation, treatment details, and follow-up documentation. For many skin cancer cases, this includes the pathology report, the procedure note or operative report, and follow-up office notes. For melanoma, the pathology report is especially important because it contains the staging features insurers rely on. When sentinel lymph node biopsy was performed, carriers often want those results. If imaging or oncology consults were part of your treatment, those records can also play a role in the file.

Underwriters also pay attention to how consistently you’ve been followed since treatment. A long gap in follow-up can make an underwriter more cautious, even if you feel well. From the insurer’s perspective, consistent follow-up demonstrates stability and reduces uncertainty. If you’ve had multiple lesions, carriers may request details for each lesion, including dates, type, treatment, and whether there was recurrence. When your documentation is complete and the timeline is clear, underwriting becomes more efficient and outcomes often improve.

If you’re trying to interpret what a rating means when you receive an offer, it can help to understand how table ratings work and why carriers apply them. This resource is a solid reference: life insurance table ratings explained.

Why Some Applicants Get Declined (and How to Avoid It)

Many declines happen for preventable reasons. The first is applying with the wrong carrier. Some companies are simply more conservative with melanoma histories or require longer waiting periods. Others may be favorable for thin lesions with clean margins and stable follow-up. If your application goes to the wrong carrier first, you risk a decline that becomes part of your insurance history and may complicate future applications.

The second is incomplete disclosure or incomplete documentation. Underwriters do not like uncertainty. When a file is missing pathology details or follow-up notes, the insurer may postpone the case or interpret it conservatively. The third is timing. If the cancer was treated recently, some carriers will postpone until you have a longer documented disease-free interval. That doesn’t mean you can’t get coverage—it often means the best path might be a different product type now, followed by re-shopping later when your timeline strengthens.

If you’ve already been declined, that doesn’t mean the door is closed. Another carrier may view the same history differently—especially if more time has passed or your follow-up documentation is stronger now. If you’re unsure how a decline affects next steps, this guide can help you reset strategy: what happens if you’re denied life insurance.

Term vs. Permanent Coverage After Skin Cancer

Most people with a skin cancer history shop term life first because it provides the most death benefit per dollar for the years that matter most—income replacement, mortgage protection, and family security. Term is often the most efficient solution when underwriting is favorable. If the case is more complex or if pricing is higher due to melanoma features, we can still compare term options across carriers to find the best value within the market’s underwriting reality.

Permanent coverage can also be appropriate, particularly when someone has long-term planning goals, wants coverage that doesn’t expire, or has estate or legacy needs. Permanent policies are underwritten more conservatively at times, and pricing can vary widely by carrier. For some applicants, a hybrid strategy works best—term for high-need years plus a smaller permanent policy for lifelong coverage. The right answer depends on goals, budget, and what the carrier market will realistically approve for your specific pathology and timeline.

If you’re still building foundational understanding, you may find these resources helpful as you compare options: how life insurance works and are life insurance benefits taxable.

What You Can Expect (Typical Outcomes)

Outcomes vary, but there are common patterns. For basal cell and many squamous cell histories, applicants are often eligible for standard to favorable outcomes once the lesion is fully treated, margins are clear, and follow-ups are consistent. For melanoma in situ or thin lesions with favorable pathology, standard outcomes may be possible after a carrier-specific disease-free period. For thicker or invasive melanoma histories, carriers may impose table ratings, postpone decisions until more time has passed, or limit product options depending on stage and history.

The key is that “insurable” and “best possible offer” are not the same thing. Many people can obtain coverage, but pricing can swing significantly based on carrier selection and documentation. Our goal is to make sure your underwriting result reflects the strongest version of your file—clear margins, stable follow-up, clean timeline—rather than a conservative interpretation created by incomplete information.

Example Case

A 54-year-old non-smoker with melanoma (0.7 mm, no ulceration, negative sentinel node) completed excision 3 years ago with clean follow-ups. Another agency projected a high table rating. We matched the case to a melanoma-friendly carrier and secured Standard Non-Smoker for $300,000 over 20 years—saving the client over $450 per year versus prior estimates. That outcome wasn’t luck. It was carrier fit plus clean documentation, presented in a way that underwriters could evaluate without filling gaps with worst-case assumptions.

Ready to see your options? Complete our secure skin cancer life insurance request form, and we’ll compare carriers and send personalized recommendations based on your diagnosis type, pathology details, and time since treatment.

Why Work With Diversified Insurance Brokers

Skin cancer underwriting is one of the clearest examples of why an independent brokerage matters. We are not tied to a single carrier’s rules, and we are not forced to “make it fit” within one underwriting philosophy. Instead, we compare underwriting appetite and pricing across carriers and place your case where your profile is most likely to be treated fairly. That approach helps clients avoid unnecessary declines, reduce underwriting delays, and improve the probability of receiving a competitive offer that actually makes sense.

We also focus on clarity and speed. We help you identify what records matter, we help you tell the timeline cleanly, and we keep the underwriting process moving so you’re not stuck in weeks of record requests and back-and-forth. If you’re shopping more broadly and want to understand what a good independent advisor relationship looks like, this resource is helpful: How to Choose the Best Independent Insurance Agent.